LB Pharmaceuticals LBRX
$38.85 −$1.19 (-2.97%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $38.85 0.00%
Open$39.53
Prev close$40.04
Day range$38.57 – $40.67
Volume303.1K
Market cap$1.26B
P/E (TTM)38.3
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$62.50M-1,091.3% YoY
Net profit-$59.07M-1,561.0% YoY
Diluted EPS-$1.79-193.4% YoY
Free cash flow-$64.36M-1,808.2% YoY
Operating cash flow-$64.29M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-38.8%
Return on assets-36.5%
Return on invested capital-40.4%
Current ratio14.78
Liabilities / assets7.9%
Cash & investments$403.76M
Total debt$4.20M
Net cash (debt)$399.56M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $62.50M | $53.92M | $22.10M | $30.40M | $13.87M |
| Selling and Admin Expenses | $10.98M | $9.77M | $7.46M | $13.66M | $5.39M |
| -General & Admin Expense | $10.98M | $9.77M | $7.46M | $13.66M | $5.39M |
| Research & Development | $51.52M | $44.15M | $14.65M | $16.74M | $8.48M |
| Operating Profit | -$62.50M | -$53.92M | -$22.10M | -$30.40M | -$13.87M |
| Net Non-Operating Interest Income (Expense) | $3.77M | $2.97M | $2.85M | $3.92M | $2.80M |
| Non-Operating Interest Income | $3.77M | $2.97M | $2.85M | $3.92M | $2.80M |
| Other Income (Expense) | -$339,000.00 | -$662,000.00 | $200,000.00 | $1.28M | -$401,000.00 |
| Gain on Sale of Security | -$339,000.00 | -$662,000.00 | $200,000.00 | $1.28M | -$401,000.00 |
| Pretax Profit | -$59.07M | -$51.60M | -$19.05M | -$25.20M | -$11.47M |
| Tax | $0.00 | $0.00 | $0.00 | $1,000.00 | $1,000.00 |
| Net Profit | -$59.07M | -$51.60M | -$19.05M | -$25.21M | -$11.47M |
| Profit from Continuing Operations | -$59.07M | -$51.60M | -$19.05M | -$25.21M | -$11.47M |
| Net Income to Parent Company | -$59.07M | -$51.60M | -$19.05M | -$25.21M | -$11.47M |
| Net Income to Common Stockholders | -$59.07M | -$51.60M | -$19.05M | -$25.21M | -$11.47M |
| Basic EPS | -$1.79 | -$1.71 | -$0.67 | -$3.13 | -$0.45 |
| Diluted EPS | -$1.79 | -$1.71 | -$0.67 | -$3.13 | -$0.45 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $453.37M | $361.69M | $393.48M | $312.93M | $312.93M |
| Total Current Assets | $447.12M | $355.30M | $389.07M | $308.43M | $308.43M |
| Cash and Cash Equivalents & Short-Term Investments | $403.76M | $327.79M | $365.64M | $295.21M | $295.21M |
| -Cash and Cash Equivalents | $215.08M | $283.11M | $320.68M | $250.17M | $250.17M |
| -Short Term Investments | $188.69M | $44.68M | $44.96M | $45.04M | $45.04M |
| Prepaid Assets | $38.69M | $26.50M | $22.65M | $12.74M | $12.74M |
| Other Current Assets | $4.67M | $1.01M | $787,000.00 | $478,000.00 | $478,000.00 |
| Total Non-Current Assets | $6.25M | $6.39M | $4.41M | $4.50M | $4.50M |
| Net PPE | $5.46M | $5.61M | $3.63M | $3.73M | $3.73M |
| -Gross PPE | $6.18M | $6.21M | $4.13M | $4.15M | $4.15M |
| -Accumulated Depreciation | -$723,000.00 | -$599,000.00 | -$502,000.00 | -$420,000.00 | -$420,000.00 |
| Other Non-Current Assets | $788,000.00 | $782,000.00 | $776,000.00 | $770,000.00 | $770,000.00 |
| Total Liabilities | $35.73M | $29.35M | $14.79M | $11.62M | $11.62M |
| Total Current Liabilities | $30.25M | $23.56M | $10.91M | $7.44M | $7.44M |
| Payables | $6.88M | $3.49M | $7.12M | $2.13M | $2.13M |
| -Accounts Payable | $6.88M | $3.49M | $7.12M | $2.13M | $2.13M |
| Current Accrued Expenses | $19.08M | $16.43M | $1.71M | $2.39M | $2.39M |
| Short-Term Debt and Capital Lease Obligation | $956,000.00 | $844,000.00 | $730,000.00 | $730,000.00 | $730,000.00 |
| -Current Capital Lease Obligation | $956,000.00 | $844,000.00 | $730,000.00 | $730,000.00 | $730,000.00 |
| Total Non-Current Liabilities | $5.48M | $5.78M | $3.88M | $4.18M | $4.18M |
| Long Term Debt and Capital Lease Obligation | $4.20M | $4.37M | $2.74M | $2.84M | $2.84M |
| -Long Term Capital Lease Obligation | $4.20M | $4.37M | $2.74M | $2.84M | $2.84M |
| Derivative Product Liabilities | $1.28M | $1.41M | $1.14M | $1.34M | $1.34M |
| Total Equity | $417.64M | $332.35M | $378.69M | $301.31M | $301.31M |
| Stockholders' Equity | $417.64M | $332.35M | $378.69M | $301.31M | $301.31M |
| Capital Stock | $3,000.00 | $3,000.00 | $3,000.00 | $3,000.00 | $3,000.00 |
| -Common Stock | $3,000.00 | $3,000.00 | $3,000.00 | $3,000.00 | $3,000.00 |
| Additional Paid-In Capital | $677.43M | $532.34M | $527.06M | $430.67M | $430.67M |
| Retained Earnings | -$259.25M | -$200.19M | -$148.58M | -$129.53M | -$129.53M |
| Gains/Losses Not Affecting Retained Earnings | -$545,000.00 | $186,000.00 | $208,000.00 | $168,000.00 | $168,000.00 |
| Convertible preferred securities | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$64.29M | -$37.63M | -$23.29M | -$35.21M | -$18.10M |
| Net cash flow from continuing operations | -$64.29M | -$37.63M | -$23.29M | -$35.21M | -$18.10M |
| Net Income from Continuing Operations | -$59.07M | -$51.60M | -$19.05M | -$25.21M | -$11.47M |
| Gain/Loss from Continuing Operations | $339,000.00 | $662,000.00 | -$200,000.00 | -$1.27M | $409,000.00 |
| Depreciation & Depletion & Amortization | $124,000.00 | $97,000.00 | $82,000.00 | $321,000.00 | $85,000.00 |
| Other Non-Cash Items | $95,000.00 | $93,000.00 | $50,000.00 | $147,000.00 | $47,000.00 |
| Change in Working Capital | -$9.07M | $8.29M | -$6.75M | -$13.65M | -$9.53M |
| -Change in Receivables | $237,000.00 | -$123,000.00 | $103,000.00 | -$268,000.00 | -$100,000.00 |
| -Change in Prepaid Assets | -$15.27M | -$4.07M | -$10.22M | -$12.34M | -$11.30M |
| -Change in Payables and Accrued Expense | $6.02M | $12.54M | $3.46M | -$910,000.00 | $1.97M |
| -Change in Other Current Liabilities | -$60,000.00 | -$57,000.00 | -$99,000.00 | -$134,000.00 | -$98,000.00 |
| Net cash flow from investing | -$144.65M | $89,000.00 | -$32,000.00 | -$39.89M | -$40,000.00 |
| Net Cash Flow from Continuing Investing Activities | -$144.65M | $89,000.00 | -$32,000.00 | -$39.89M | -$40,000.00 |
| Net PPE Purchase and Sale | -$70,000.00 | -$363,000.00 | -$32,000.00 | -$52,000.00 | -$40,000.00 |
| Net Investment Purchase and Sale | -$144.58M | $452,000.00 | $0.00 | -$39.84M | $0.00 |
| Financing Cash Flow | $140.92M | -$19,000.00 | $93.83M | $302.56M | -$1.17M |
| Net Cash Flow from Continuing Financing Activities | $140.92M | -$19,000.00 | $93.83M | $302.56M | -$1.17M |
| Net Common Stock Issuance | $150.00M | $0.00 | $100.00M | $327.75M | $0.00 |
| Proceeds from Stock Option Exercised | $42,000.00 | $48,000.00 | $29,000.00 | $247,000.00 | $0.00 |
| Net Other Financing Charges | -$9.13M | -$67,000.00 | -$6.20M | -$25.44M | -$1.17M |
| Ending Cash Balance | $215.86M | $283.89M | $321.45M | $250.94M | $250.94M |
| Net Change in Cash | -$68.03M | -$37.56M | $70.51M | $227.47M | -$19.31M |
| Beginning Cash Balance | $283.89M | $321.45M | $250.94M | $23.48M | $270.26M |
| Free Cash Flow | -$64.36M | -$37.99M | -$23.32M | -$35.26M | -$18.14M |
| Net Preferred Stock Issuance | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on LBRX.
Sign in to join the discussion.